GPCR
Structure Therapeutics Inc.Healthcare·Biotechnology
$39.34
$2.3B market cap
Revenue
$0.0M
Free Cash Flow
$-51.8M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for
2-Year Price History
$39.19+14.6%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -88.4 | -89.7 | -76.2 | 15.3 | 14.1 | -1.2 | 1,459 | 5.8 | 72.4 | -85.0% | -- | -- |
| Act | 2025-Q4 | 0.0 | 33.6 | 24.0 | 33.0 | -64.4 | -65.9 | -1.5 | 1,446 | 6.5 | 59.2 | 19.1% | -- | -- |
Valuation & Metrics
Market Stats
Price$39.34
Market Cap$2.3B
Enterprise Value$812M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-2.3%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-43.2M
Free Cash Flow$-51.8M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-33.0%
WC Change % Rev0.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares6.0M
Days to Cover6.8
Change (vs Prior)-2.8%
Need at least 2 settlement dates for chart
Employees
Headcount163
Revenue / Employee$0
Gross Profit / Employee$-7,476
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
140.9%(+97.6% YoY)
185 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
1.2%(+0.7% YoY)
3 filers
Vanguard, iShares, SPDR
Market makers
2.8%(+2.4% YoY)
5 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| FMR LLC | $405M | $47.53 | −$14.9M | +$121M | -0.0% | $1.89T |
| WELLINGTON MANAGEMENT GROUP LLP | $350M | $45.87 | +$6.7M | −$25.6M | -0.3% | $533.98B |
| Avoro Capital Advisors LLC | $316M | $42.89 | +$0 | +$316M | +1.3% | $10.15B |
| JANUS HENDERSON GROUP PLC | $258M | $44.48 | +$12.8M | +$48.2M | +1.2% | $209.29B |
| Deep Track Capital, LP | $206M | $25.98 | +$8.1M | +$8.7M | -1.4% | $4.85B |
| BVF INC/IL | $167M | $32.47 | −$948K | +$81.4M | -0.3% | $3.14B |
| MORGAN STANLEY | $111M | $51.70 | +$10.5M | +$77.7M | -0.3% | $1.65T |
| PRICE T ROWE ASSOCIATES INC /MD/ | $96.4M | $47.94 | +$15.9M | +$59.0M | -0.2% | $864.93B |
| PRINCIPAL FINANCIAL GROUP INC | $84.5M | $48.02 | +$22.6M | +$48.1M | -0.5% | $186.29B |
| DRIEHAUS CAPITAL MANAGEMENT LLC | $76.0M | $45.07 | −$3.1M | +$14.7M | +0.3% | $13.60B |
| ORBIMED ADVISORS LLC | $71.1M | $33.59 | +$15.1M | +$39.7M | -8.1% | $4.38B |
| AMERICAN CENTURY COMPANIES INC | $69.3M | $45.38 | +$44.9M | +$44.7M | +0.7% | $193.48B |
| BAKER BROS. ADVISORS LP | $69.0M | $22.23 | +$0 | +$51.6M | -0.5% | $16.13B |
| Siren, L.L.C. | $64.0M | $33.42 | +$12.1M | +$64.0M | +6.1% | $3.61B |
| Casdin Capital, LLC | $56.6M | $29.83 | +$0 | +$22.9M | -3.3% | $1.32B |
| CAPITOLIS LIQUID GLOBAL MARKETS LLCMM | $55.5M | $64.49 | +$13.2M | +$55.5M | +0.1% | $15.72B |
| ALLIANCEBERNSTEIN L.P. | $44.4M | $64.88 | −$10.1M | +$44.4M | -0.3% | $307.70B |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | $37.0M | $44.71 | +$0 | +$19.0M | -0.8% | $7.18B |
| PACIFIC HEIGHTS ASSET MANAGEMENT LLC | $36.1M | $24.89 | +$2.4M | +$36.1M | +0.3% | $2.99B |
| Rock Springs Capital Management LP | $30.9M | $39.07 | −$5.2M | −$23.8M | -2.0% | $1.65B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BULLISH
Holders
-0.03%
avg per quarter
Holders (ex-self)
-0.04%
excl. this stock
Buyers (this Q)
+0.61%
55 buyers · $0.15B in
Sellers (this Q)
-0.15%
65 sellers · $0.70B out
alpha coverage: 99% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
-16.9%
how holders react when this stock falls
On quiet Qs
+17.9%
−10% to +10% baseline
On rallies (+10%+)
+14.6%
how they react when this stock rises
Holders' portfolio flow this Q
+0.1%
inflows — adds are organic
Sellers' portfolio flow this Q
-0.8%
Sellers' overall flow ~ flat.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-4.3%
Holder mid (any stock)
-2.3%
Holder rally (any stock)
-3.7%
Biggest decreases this quarter
CITADEL ADVISORS LLCexited−$53.7MFARALLON CAPITAL MANAGEMENT LLCexited−$31.6MEcoR1 Capital, LLCexited−$23.3MCapricorn Fund Managers Ltdexited−$17.6MFRANKLIN RESOURCES INC−$16.3Mα-0.2FMR LLC−$14.9Mα-0.0JANE STREET GROUP, LLCexited−$10.2MALLIANCEBERNSTEIN L.P.−$10.1Mα-0.3Alyeska Investment Group, L.P.exited−$8.0MRTW INVESTMENTS, LPexited−$7.0M
Top-5 holders · 47.7%
FMR LLC--
WELLINGTON MANAGEMENT GROUP LLP--
Avoro Capital Advisors LLC--
JANUS HENDERSON GROUP PLC--
Deep Track Capital, LP--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
FMR LLC8.4MWELLINGTON MANAGEMENT GROUP LLP7.3MAvoro Capital Advisors LLC6.6MJANUS HENDERSON GROUP PLC5.4MDeep Track Capital, LP4.3MBVF INC/IL3.5MCapital Research Global Investors—MORGAN STANLEY2.3MPRICE T ROWE ASSOCIATES INC /MD/2.0MDRIEHAUS CAPITAL MANAGEMENT LLC1.6M
Related Stocks
Investors who own this also own
Stocks held by the same active managers as this one, ranked by score — how much more often these appear together than random chance (1× = baseline). Excludes index ETFs and market makers; minimum 3 shared holders.
| Ticker | Name | Co-holders | Score |
|---|---|---|---|
| TSHA | Taysha Gene Therapies, Inc. | 3 | 132.75× |
| MANE | Veradermics, Incorporated | 3 | 118.00× |
| STOK | Stoke Therapeutics, Inc. | 3 | 118.00× |
| CMPX | Compass Therapeutics, Inc. | 3 | 106.20× |
| OLMA | Olema Pharmaceuticals, Inc. | 3 | 106.20× |
| RARE | Ultragenyx Pharmaceutical Inc. | 4 | 101.14× |
| ARGX | argenx SE | 5 | 88.50× |
| XENE | Xenon Pharmaceuticals Inc. | 5 | 84.29× |
| ELVN | Enliven Therapeutics, Inc. | 4 | 83.29× |
| IMVT | Immunovant, Inc. | 3 | 81.69× |
| ORKA | Oruka Therapeutics, Inc. | 4 | 78.67× |
| OCUL | Ocular Therapeutix, Inc. | 3 | 75.86× |
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (2 analysts)$123.0021270.0%
Last Year (10 analysts)$102.8016130.0%
Current Price$39.34
Analyst Ratings
14
Buy: 14Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Major holders (≥10% beneficial owners)
Buys ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Sells ($, 12mo)
$0
4 txns · 1 insider · 113,570 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-04-14 | SELL | FMR LLC | 10 percent owner, other: See Remark 1 | 17,452 | $0.00 | $0 | $0 |
| 2026-01-15 | SELL | FMR LLC | 10 percent owner, other: See Remark 1 | 17,452 | $0.00 | $0 | $0 |
| 2025-12-08 | SELL | FMR LLC | 10 percent owner, other: See Remark 1 | 52,356 | $0.00 | $0 | $0 |
| 2025-07-30 | SELL | FMR LLC | 10 percent owner, other: See Remark 1 | 26,310 | $0.00 | $0 | $0 |
Order Flow (FINRA, ~3w lag)
16.2%retail+4.8pp
31.7%dark-4.6pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Structure Therapeutics Inc.: Accelerated Burn and Strategic Dilution Amid Clinical Expansion
Overall Risk
4/10
Fraud
2/10
Dilution
7/10
Insolvency
2/10
Earnings Overstated
2/10
Hidden Liabilities
4/10
Legal
3/10
Audit Warnings
2/10
Hidden Upside
6/10
Contextually Acceptable
8/10